William Blair Brokers Reduce Earnings Estimates for ANRO

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at William Blair cut their Q2 2025 earnings estimates for Alto Neuroscience in a research report issued on Thursday, May 15th. William Blair analyst M. Minter now expects that the company will earn ($0.55) per share for the quarter, down from their prior forecast of ($0.51). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience's Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.21) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($2.91) EPS and FY2029 earnings at ($1.43) EPS.

Several other brokerages have also recently issued reports on ANRO. Wedbush restated a "neutral" rating and issued a $4.00 target price on shares of Alto Neuroscience in a report on Thursday, May 15th. HC Wainwright started coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They issued a "buy" rating and a $10.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, Alto Neuroscience presently has a consensus rating of "Moderate Buy" and an average target price of $15.40.

Alto Neuroscience Stock Performance

ANRO stock traded up $0.12 on Monday, hitting $3.05. The company had a trading volume of 276,114 shares, compared to its average volume of 385,196. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $17.55. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The stock's 50-day simple moving average is $2.35 and its 200 day simple moving average is $3.40. The stock has a market cap of $82.68 million, a price-to-earnings ratio of -1.31 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.06.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANRO. Barclays PLC raised its position in Alto Neuroscience by 872.7% in the third quarter. Barclays PLC now owns 29,599 shares of the company's stock worth $339,000 after acquiring an additional 26,556 shares during the period. JPMorgan Chase & Co. raised its position in Alto Neuroscience by 543.4% in the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company's stock worth $278,000 after acquiring an additional 20,536 shares during the period. Rhumbline Advisers raised its position in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after acquiring an additional 5,008 shares during the period. Bank of New York Mellon Corp raised its position in Alto Neuroscience by 15.0% in the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company's stock worth $221,000 after acquiring an additional 6,812 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Alto Neuroscience during the 4th quarter valued at $74,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.